[{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Xellia Pharmaceuticals ApS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Phenylephrine HCl","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ethanol","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zonisamide","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Crossject","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Crossject"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Novitium Pharma LLC","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Carglumic Acid","moa":"CPS1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Cysteine Hydrochloride","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Eton Pharmaceuticals \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Dr. Reddy\u2019s Laboratories"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eton Pharmaceuticals \/ Azurity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Azurity Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Betaine","moa":"Methylation","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ethanol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Tulex Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"ET-600","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Betaine","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dehydrated Alcohol","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Nitisinone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eton Pharmaceuticals \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Eton Pharmaceuticals \/ Eton Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Eton Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Eton will acquire Increlex (mecasermin injection) from Ipsen, which is indicated for treating patients suffering from SPIGFD because their bodies do not make enough IGF-1.

                          Brand Name : Increlex

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 03, 2024

                          Lead Product(s) : Mecasermin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Recipient : Ipsen

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.

                          Brand Name : ET-400

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 15, 2024

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.

                          Brand Name : ET-400

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 30, 2024

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through the acquisition, Eton gains access to an abbreviated new drug application for Nitisinone Capsules via Oakrum. Nitisinone is FDA approved or the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine ...

                          Brand Name : Nitisinone-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 04, 2023

                          Lead Product(s) : Nitisinone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Recipient : Oakrum Pharma, LLC

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : FDA issued a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning.

                          Brand Name : Undsclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 28, 2023

                          Lead Product(s) : Ethanol

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Betaine anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood levels. The program will provide prescription fulfillment, insurance benefits investigation, educational suppo...

                          Brand Name : Cystadane-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 10, 2023

                          Lead Product(s) : Betaine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through the acquisition, Eton will expand its portfolio with ET-600 which is an innovative product candidate under development for the treatment of an endocrinology condition.

                          Brand Name : ET-600

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 15, 2023

                          Lead Product(s) : ET-600

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : Tulex Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : USFDA has accepted for review the company’s NDA response for dehydrated alcohol injection (a nerve blocking agent) for the proposed indication of methanol poisoning.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 11, 2023

                          Lead Product(s) : Ethanol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Betaine shares the same prescriber base as the carglumic acid tablets, so it is an attractive opportunity to leverage the existing commercial infrastructure.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 13, 2022

                          Lead Product(s) : Betaine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Recipient : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Zonisade is the first and only zonisamide formulation for oral liquid administration to be approved by the US Food and Drug Administration as an adjunctive therapy for the treatment of partial seizures in adults and paediatric patients aged 16 years and ...

                          Brand Name : Zonisade

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 18, 2022

                          Lead Product(s) : Zonisamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Azurity Pharma

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank